You can buy or sell Verastem and other stocks, options, ETFs, and crypto commission-free!
Verastem, Inc. Common Stock, also called Verastem, is a biopharmaceutical company focusing on developing and commercializing medicines to improve the survival and quality of life of cancer patients. Read More It markets COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K) and dual inhibitor of PI3K-delta and PI3K-gamma, which is indicated for the treatment of adult patients with relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma after at least two prior therapies and relapsed or refractory follicular lymphoma (FL) after at least two prior systemic therapies. The indication in FL is approved under accelerated approval based on overall response rate. In addition, it is developing the focal adhesion kinase inhibitor defactinib, which is being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of various different cancer types, including pancreatic cancer, ovarian cancer, non-small cell lung cancer (NSCLC), and mesothelioma. Verastem, Inc. has collaboration agreements with Yakult Honsha Co., Ltd., CSPS Pharmaceutical Group Limited and The Leukemia & Lymphoma Society. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.
52 Week High
52 Week Low
Verastem: Copiktra To Power Turnaround Prospect
To investors' disappointment, Copiktra posted subpar sales after two quarters into launch. Consequently, the stock is depreciating like a falling knife that has yet to find a base. "It's far better to buy a wonderful company at a fair price than a fair company at a wonderful price." - Warren Buffett I enjoy conducting investment research because of the intellectual challenges that each unique company presents. And, I feed off the excitement associated with putting together various puzzle pieces into a gra...
Seeking AlphaMay 19
Verastem: A Speculative Buy
In my last Verastem (VSTM) article, I provided evidence for a speculative buy in VSTM in anticipation of COPIKTRA starting to gain traction in its second quarter on the market.
Seeking AlphaMay 9
Verastem, Inc. CEO Robert Forrester on Q1 2019 Results - Earnings Call Transcript
Verastem, Inc. (NASDAQ:VSTM) Q1 2019 Earnings Conference Call May 9, 2019 4:30 PM ET Company Participants John Doyle - VP, IR Robert Forrester - President, CEO & Director Joseph Lobacki - EVP & Chief Commercial Officer Daniel Paterson - COO Robert Gagnon - CFO Conference Call Participants James Colby - BTIG Sean Lee - H.C. Wainwright & Co. George Zavoico - B. Riley FBR, Inc. Matthew Cross - JonesTrading Institutional Services Operator Good afternoon, and welcome to the Verastem Oncology Investo...
Expected Aug 8, After Hours